Bank of America Corp DE Acquires 71,827 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Bank of America Corp DE grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 21.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 404,902 shares of the biopharmaceutical company's stock after purchasing an additional 71,827 shares during the period. Bank of America Corp DE owned approximately 0.71% of Agios Pharmaceuticals worth $13,305,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in AGIO. Venturi Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $53,000. Sterling Capital Management LLC boosted its stake in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 1,587 shares during the last quarter. KBC Group NV grew its holdings in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 2,338 shares during the last quarter.

Agios Pharmaceuticals Stock Up 1.3%

NASDAQ:AGIO traded up $0.40 during trading hours on Tuesday, hitting $30.20. 548,357 shares of the company's stock traded hands, compared to its average volume of 694,810. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The business's fifty day simple moving average is $28.57 and its two-hundred day simple moving average is $35.67. The firm has a market cap of $1.75 billion, a P/E ratio of 2.66 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective on the stock. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Scotiabank cut their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $56.00.

Insider Activity at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.